What is William Blair’s Forecast for RCKT Q3 Earnings?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Analysts at William Blair dropped their Q3 2026 EPS estimates for Rocket Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 20th. William Blair analyst S. Corwin now forecasts that the biotechnology company will post earnings per share of ($0.41) for the quarter, down from their prior estimate of ($0.38). The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share. William Blair also issued estimates for Rocket Pharmaceuticals’ Q4 2026 earnings at ($0.54) EPS and FY2026 earnings at ($1.60) EPS.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). During the same quarter in the previous year, the company earned ($0.74) EPS.

RCKT has been the subject of a number of other reports. The Goldman Sachs Group cut Rocket Pharmaceuticals from a “neutral” rating to a “sell” rating in a research note on Wednesday, May 28th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Rocket Pharmaceuticals in a research note on Wednesday, May 28th. Chardan Capital reaffirmed a “buy” rating and issued a $11.00 price target on shares of Rocket Pharmaceuticals in a research note on Wednesday. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Rocket Pharmaceuticals in a research report on Wednesday, May 28th. Finally, Evercore ISI lowered Rocket Pharmaceuticals from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a research report on Friday, May 30th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $16.73.

Rocket Pharmaceuticals Stock Performance

Shares of RCKT stock opened at $3.64 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.39 and a quick ratio of 6.39. The stock has a market cap of $392.76 million, a PE ratio of -1.45 and a beta of 0.65. The stock has a 50-day moving average of $2.99 and a 200-day moving average of $5.66. Rocket Pharmaceuticals has a one year low of $2.19 and a one year high of $22.01.

Insider Buying and Selling at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, insider Jonathan David Schwartz sold 11,161 shares of Rocket Pharmaceuticals stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $3.02, for a total value of $33,706.22. Following the sale, the insider directly owned 224,094 shares in the company, valued at approximately $676,763.88. The trade was a 4.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Martin Wilson sold 12,109 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $3.02, for a total value of $36,569.18. Following the completion of the sale, the general counsel directly owned 137,054 shares of the company’s stock, valued at approximately $413,903.08. The trade was a 8.12% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 36,927 shares of company stock worth $111,413 over the last quarter. Company insiders own 24.76% of the company’s stock.

Institutional Trading of Rocket Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in RCKT. Wells Fargo & Company MN lifted its stake in Rocket Pharmaceuticals by 40.9% in the fourth quarter. Wells Fargo & Company MN now owns 34,970 shares of the biotechnology company’s stock valued at $440,000 after acquiring an additional 10,147 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in Rocket Pharmaceuticals by 4.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 32,422 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 1,280 shares during the last quarter. Invesco Ltd. lifted its stake in Rocket Pharmaceuticals by 1.5% in the fourth quarter. Invesco Ltd. now owns 357,840 shares of the biotechnology company’s stock valued at $4,498,000 after acquiring an additional 5,218 shares during the last quarter. Legal & General Group Plc lifted its stake in Rocket Pharmaceuticals by 3.3% in the fourth quarter. Legal & General Group Plc now owns 75,454 shares of the biotechnology company’s stock valued at $948,000 after acquiring an additional 2,416 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in Rocket Pharmaceuticals in the fourth quarter valued at $2,747,000. Institutional investors and hedge funds own 98.39% of the company’s stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.